Despite intensive clinical study the overall survival for patients with lung cancer remains dismally short. The advent of aggressive chemotherapy has had only minimal impact on the survival of those patients with metastatic disease (Souhami, 1984) . New approaches to provide selective tumour cell destruction are therefore urgently needed. The demonstration that human cancer cells express unique segments of DNA, called oncogenes, provides an exciting new avenue for clinical investigation (Bishop, 1984; Cooper & Lane, 1984) . Over 25 of these genes have been identified, molecularly cloned and sequenced. Changes in the coding or control regions of these genes have been implicated in the development of several tumour types including bronchial carcinoma (Krontiris, 1983; Der & Cooper, 1983) . New strategies for systemic therapy may emerge by understanding more about these genes and their products.
There is now good evidence that the proteins coded for by oncogenes are involved in growth control. At least one (c-sis) is related to a growth factor (Waterfield et al., 1983) . and another (c-erb-B) to the internal component of the surface receptor for a growth factor (Downward et al., 1984) . The c-myc gene product is particularly intriguing with regard to human cancer. Several studies have shown that this oncoprotein regulates cell division and differentiation (Rabbitts et al., 1985; Pfeifer-Ohlsson et al., 1984) . the protein itself have unusually short half lives of 20-30min, a prerequisite for their putative cell cycle control function (Pauza & Evan, 1986) . Furthermore the level of c-myc mRNA increases as an early event when cells are stimulated into division (Kelly et al., 1983) . The c-myc gene has been found to be amplified in several lung cancer cell lines (Little et al., 1983) . Levels of c-myc RNA have also been noted to be elevated in biopsy samples from lung tumours of several histological types.
In order to examine the relevance of the c-myc oncoprotein in clinical samples we have constructed a set of monoclonal antibodies (MCAs) by immunisation with synthetic peptides (Evan et al., 1985) . The DNA sequence of the c-myc gene was used to predict the amino acid structure of the oncoprotein. Two peptides of 18 and 32 amino acids in length were synthesised. The regions chosen for synthesis and immunisation were predicted to be exposed within the intact molecule by assessing the relative hydrophobicity of different parts of the sequence. Six MCAs were produced that reacted to the 62,000 dalton protein identifiable with the cmyc product (p62c-mYc) (Evan et al., 1985) .
A possible tool in the detection and localisation of tumours is a suitably labelled tumour specific antibody. Several studies have shown that both polyclonal and monoclonal antibodies against cell surface antigens can effectively localise tumours (Mach et al., 1981; Smedley et al., 1983) . However, the images obtained could be improved by the use of more tumour specific reagents. After labelling with radioiodine, one anti c-myc gene product antibody was found to localise human tumour xenografts in immunosuppressed mice. This antibody was therefore evaluated for its ability to localise bronchial carcinoma in patients.
Materials and methods
Monoclonal antibody production Peptide synthesis, the immunisation protocol and screening procedures for deriving CT14 MCA (an IgGiK) are described elsewhere (Evan et al., 1985 Clinical studies Informed consent was obtained from all patients. Potassium iodide tablets (120mg daily) were given orally for 2 days, from the day of antibody injection, to block thyroid uptake of radioiodine. One mg of CT14 labelled with 1 mCi 1311 in l0 ml normal saline was injected i.v. Serum samples in 6 patients were collected at 0, 1, 2, 4, 8, 24, 48 h after the administration of CT14. The samples were counted for 1311 activity both before and after TCA precipitation to determine protein bound and free 131 . Scanning using a gamma camera (IGE480) was performed at 24 h and 48 h after antibody injection. Thirty minutes prior to each scan patients were given 0.5 mCi of a standard technetium labelled human serum albumin (HSA) i.v. to delineate the blood pool.
Images of the distribution of HSA and CT14 were recorded on a Nodecrest computer which simultaneously recorded the energy peaks of 99MTc and 13'I respectively. The ratio of 1311 and 99MTc counts over the ventricular chambers, which is predominantly blood pool in nature, provides the standard for correction of circulatory antibody. The computer subtracts the 1311 image, pixel by pixel using this standard and produces an image which represents, by means of colour variation, areas of high concentration of bound 1311 antibody. Twenty patients with histologically proven cancer were studied: 14 with primary bronchial carcinoma; 4 with pulmonary metastases from tumours at other sites and 2 with localised primary tumours at sites outside the thorax.
Results
Results of the ELISA assay (Figure 1) showed that the 131-iodine labelled CT14 MCA has retained its affinity to the synthetic peptide. Figure 2 shows the serum levels of 1311, measured as radioactivity per ml of blood detected by a gamma counter. Trichloroacetic acid precipitation showed that 90% of the 1311 remained protein bound. The mean half life of CT14-1311 was 20h and the slope of decay similar in all patients studied.
Good tumour localisation was seen in 12 out of 14 patients with primary bronchial carcinoma ( tumour images had documented evidence of metastatic disease in liver, bone and brain. However, there was no evidence of increased uptake at the sites of metastases.
None of the 6 patients with pulmonary metastases showed tumour localisation. These patients all had multiple small metastases each less than 2cm diameter (Table II) . A patient with a primary glioma and another with locally recurrent rectal carcinoma gave no evidence of increased uptake within the thorax.
A control study was performed using I mg of non-specific mouse IgG labelled with 1 mCi 1311. Figure 4d shows the image obtained in a control scan in patient 5 whose primary lung tumour clearly demonstrated increased uptake of CT14-131I. This scan was performed 7 days after the administration of labelled MCA. No evidence of tumour uptake was observed. 
Discussion
We believe this to be the first report of tumour localisation by a monoclonal antibody against an oncogene product. In the majority of patients with primary bronchial carcinoma good tumour localisation corresponding to the chest X-ray and CT scan images was seen. There is good evidence from immunoprecipitation and immunoblotting data with fresh tumour lysates that CT14 binds specifically to p62c-mYc . Furthermore, high levels of c-myc RNA have been reported in primary bronchial carcinomas indicating that the c-myc oncoprotein is likely to be abundant (Slamon et al., 1984) .
The c-myc protein is normally associated with cell nuclei. From this site that it is thought to exert a controlling function on cell division and differentiation. In large primary tumours, cell death will release nuclear contents into the surrounding extracellular space. It is presumably here that p62c-mYc is being detected by radiolabelled MCA. Patients with small primary or metastatic tumours showed no tumour localisation. This may well be due to lack of sufficient tumour necrosis to significantly increase the extracellular p62c-mYc level to detectable levels.
Because of their low sensitivity, it is unlikely that such scans will be useful in detecting disease not visualised by conventional radiological means. However, the level of p62c-mYc in and around a tumour may provide a new biological pointer to tumour behaviour and response to therapy. The prompt disappearance of p62c-myc image shortly after chemotherapy may be the earliest indication of tumour response. Furthermore, the shedding of this oncoprotein by tumour cells into the blood stream could well provide a new marker of tumour load. The development of a suitable assay to test this hypothesis is currently in progress. 
